In TNBC, targeting DCLK1 eliminates the malignant phenotype of cancer cells, enhances chemotherapy efficacy, and stimulates antitumor immunity by inhibiting the IL-6/STAT3 pathway [209]. This evidence concerns the gene IL6 and cancer.